(Sharecast News) - Commercial-stage biopharmaceuticals company Amryt Pharma announced the signing of multi-regional distribution agreements with Medison Pharma on Thursday.
The AIM-traded firm said the agreement would see the distribution of 'Juxtapid', or lomitapide, in Canada. and 'Lojuxta', or lomitapide, and 'Myalept', or metreleptin, in Israel.
"Today's announcement is another positive development as we continue to grow our commercial assets in existing and new territories and we further progress towards our goal of becoming a global leader in rare and orphan diseases," said chief executive officer Dr Joe Wiley.
"We are excited to be working with Medison to leverage their expertise and presence in these territories."
At 1254 GMT, shares in Amryt Pharma were up 3.36% at 211.89p.
11 Jan 2022 14:39
IN BRIEF: Amryt Pharma delists from AIM as trading shifts to New York
IN BRIEF: Amryt Pharma delists from AIM as trading shifts to New York